SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $13,146.30 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Daan Van sold 2,705 shares of the stock in a transaction on Monday, April 6th. The shares were sold at an average price of $4.86, for a total value of $13,146.30. Following the completion of the sale, the insider owned 356,069 shares in the company, valued at approximately $1,730,495.34. This trade represents a 0.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Thursday, March 19th, Well Daan Van sold 684 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $3,276.36.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ:SOPH traded down $0.04 on Wednesday, hitting $4.86. The company had a trading volume of 71,758 shares, compared to its average volume of 188,492. The stock has a market cap of $332.86 million, a price-to-earnings ratio of -9.53 and a beta of 1.04. The stock has a 50 day moving average price of $4.78 and a 200 day moving average price of $4.68. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SOPH shares. Guggenheim boosted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research restated a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $7.00.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Multiple insiders executed pre-arranged Rule 10b5-1 sales to cover tax obligations — CEO Jurgi Camblong, President Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma, and others. Collectively ~25,000 shares were sold over April 6–7 for roughly $120k at an average price near $4.85–$4.88. Executives still retain large positions, and filings note these were routine plan-driven sales rather than opportunistic exits. CEO Form 4 President Form 4 Insider Form 4

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SOPH. Alta Wealth Advisors LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at $6,708,000. Akre Capital Management LLC increased its position in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Renaissance Technologies LLC raised its stake in SOPHiA GENETICS by 169.5% in the fourth quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock valued at $388,000 after purchasing an additional 52,200 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the period. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.